Swedish scientists develop scaffold for bone regeneration

Researchers at Lund University in Sweden have created a cell-free cartilage scaffold that guides the body to repair damaged bone. The innovation, tested successfully in animal models, avoids strong immune reactions and offers a universal alternative to patient-specific grafts. Plans are underway to test it in human clinical trials.

Bone and skeletal injuries often lead to long-term disability worldwide, particularly in cases involving cancer treatment, severe joint diseases like rheumatoid arthritis and osteoarthritis, or serious infections. When large bone sections are damaged, the body may not repair them naturally, necessitating transplants. Each year, more than two million people undergo bone graft procedures globally.

Traditional methods rely on a patient's own tissue or cells, which prove expensive, time-intensive, and physically demanding. They also drive up healthcare costs. To address these issues, scientists at Lund University engineered a cartilage scaffold through decellularization: they grew cartilage tissue in the lab and removed all living cells, preserving the extracellular matrix. This matrix retains structural support and natural growth factors that signal the body to rebuild bone.

Placed at injury sites, the scaffold serves as a blueprint for regeneration without triggering significant immune responses. In animal studies, it effectively repaired large bone defects. "Patient-specific grafts are both costly and time-consuming and do not always succeed. A universal approach in tissue engineering, with a reproducible manufacturing process, offers major advantages," said Alejandro Garcia Garcia, an associate researcher in molecular skeletal biology at Lund University.

The scaffold uses stable cell lines for consistent production, enabling 'off-the-shelf' availability. It can be made in advance, stored, and used across patients without customization. "The cartilage structure we have developed is based on stable, well-controlled and reproducible cell lines, and can stimulate bone formation without triggering strong immune reactions. We show that it is possible to create a ready-made... graft that... can repair large bone defects," explained Paul Bourgine, the study's lead researcher and an associate professor at Lund University.

Future efforts will standardize large-scale manufacturing and prepare for ethical and regulatory approvals. Initial human trials may target severe defects in long bones of the arms and legs.

Makala yanayohusiana

Lab-grown spinal cord organoid model showing injury repair: inflammation and scarring on one side, reduced scars and nerve regrowth after experimental 'dancing molecules' therapy on the other.
Picha iliyoundwa na AI

Lab-grown human spinal cord organoids show signs of repair after simulated injury, Northwestern study reports

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

Northwestern University researchers say they developed an advanced lab-grown human spinal cord organoid model that reproduces key features of traumatic injury—such as inflammation and glial scarring—and that an experimental “dancing molecules” therapy reduced scar-like tissue and promoted nerve-fiber growth in the model.

Scientists at ETH Zurich have invented a hydrogel implant that mimics the body's natural bone healing process. Composed mostly of water, the material can be precisely shaped using lasers to create detailed structures resembling bone tissue. This innovation aims to offer a better alternative to traditional grafts and metal implants.

Imeripotiwa na AI

An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.

Researchers at UCLA have identified senescent immune cells, dubbed 'zombie' cells, that accumulate in aging livers and contribute to fatty liver disease. By eliminating these cells in mice, the team reversed liver damage and reduced body weight, even on an unhealthy diet. The findings, published in Nature Aging, suggest similar mechanisms may drive human liver conditions.

Imeripotiwa na AI

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa